MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

Search

Sanofi

Chiusa

48.73 0.87

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

48.34

Massimo

48.94

Metriche Chiave

By Trading Economics

Entrata

-1.1B

2.8B

Vendite

2.4B

13B

P/E

Media del settore

15.645

78.892

Margine di Profitto

21.276

Dipendenti

82,878

EBITDA

2.3B

4.2B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+68.05% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-5.9B

117B

Apertura precedente

47.86

Chiusura precedente

48.73

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Sanofi Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 dic 2025, 11:40 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal -- Update

24 dic 2025, 11:17 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

Dynavax Shares Leap Premarket on Takeover by Sanofi

24 dic 2025, 06:55 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal

15 dic 2025, 10:11 UTC

I principali Market Mover

Sanofi Shares Fall After Multiple Sclerosis Drug Gets Hit by Double Setback

24 ott 2025, 08:29 UTC

Utili

Sanofi Earnings Get Boost From Dupixent, New Drugs as U.S. Talks Continue -- Update

24 ott 2025, 07:00 UTC

Utili

Sanofi Earnings Driven by New Medicine Sales, Dupixent Performance

24 dic 2025, 17:08 UTC

Acquisizioni, Fusioni, Takeovers

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dic 2025, 12:59 UTC

Acquisizioni, Fusioni, Takeovers

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dic 2025, 06:41 UTC

Acquisizioni, Fusioni, Takeovers

Correct: Sanofi: Deal Expected to Have No Impact on 2025 Guidance

24 dic 2025, 06:19 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: Acquisition to Close in 1Q of 2026

24 dic 2025, 06:19 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: Deal Expected to Have on Impact on 2025 Guidance

24 dic 2025, 06:19 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: Offering $15.50 a Share in Cash for Dynavax

24 dic 2025, 06:18 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi to Start Cash Tender Offer at Equity Value of $2.2B

24 dic 2025, 06:18 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: Deal Adds Marketed Adult Hepatitis B Vaccine, Phase 1/2 Shingles Candidate

24 dic 2025, 06:17 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi to Buy Vaccine Company Dynavax Technologies

24 dic 2025, 06:16 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi to Buy Dynavax

24 dic 2025, 06:15 UTC

Acquisizioni, Fusioni, Takeovers

Press Release: Sanofi To Acquire Dynavax, Adding A Marketed Adult Hepatitis B Vaccine And Phase 1/2 Shingles Candidate To The Pipeline >SAN.FR

15 dic 2025, 15:03 UTC

Discorsi di Mercato

Sanofi Multiple Sclerosis Trial Failure Leaves FDA Approval in Doubt -- Market Talk

15 dic 2025, 13:59 UTC

Azioni calde

Stocks to Watch Monday: iRobot, Tilray, EchoStar, Juventus -- WSJ

15 dic 2025, 11:18 UTC

Discorsi di Mercato

Sanofi's Multiple Sclerosis Drug Fails Late-Stage Trial; Latest Pipeline Setback -- Market Talk

15 dic 2025, 09:53 UTC

Azioni calde

Stocks to Watch Monday: iRobot, EchoStar, Rocket Lab, Alibaba -- WSJ

4 dic 2025, 10:02 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi Completes Acquisition of Vicebio

4 dic 2025, 10:01 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi Buys Vicebio

4 dic 2025, 10:00 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi Completes Acquisition Of Vicebio >SAN.FR

24 ott 2025, 08:21 UTC

Discorsi di Mercato
Utili

Sanofi Results Reflect Improved Efficiency, Should Ease Margin Worries -- Market Talk

24 ott 2025, 07:56 UTC

Discorsi di Mercato
Utili

Sanofi's Dupixent Drives Growth, But Lantus Gains Set to Fade -- Market Talk

24 ott 2025, 05:30 UTC

Utili

Sanofi 3Q Adj EPS EUR2.91

24 ott 2025, 05:30 UTC

Utili

Sanofi Backs 2025 View

24 ott 2025, 05:30 UTC

Utili

Analysts Saw Sanofi 3Q Business Net Profit at EUR3.29B

24 ott 2025, 05:30 UTC

Utili

Sanofi 3Q Business Net Profit at EUR3.55B

Confronto tra pari

Modifica del prezzo

Sanofi Previsione

Obiettivo di Prezzo

By TipRanks

68.05% in crescita

Previsioni per 12 mesi

Media 81.25 USD  68.05%

Alto 117.762 USD

Basso 57 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sanofi - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

4 ratings

2

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

51.665 / 52.38Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bullish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
help-icon Live chat